Anteris Technologies Global Corp. AVR R2KR3KPHARMA
Company Overview
Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue +63.3%.
- 5-Year Trend Long-term compounding — revenue CAGR -31.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -31.51% |
| 1 Year: | 63.30% |
Stock Price Performance
| 1 Year: | +44.58% |
| 6 Months: | +5.20% |
| 3 Months: | -28.15% |
| 1 Month: | -23.27% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)25.71 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -31.5% CAGR over 5 years.
- Trading 44.5% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AVR Anteris Technologies Global Corp. R2KR3KPHARMA | 5.87 | -3.01 | $571.40M | 0.00% | - | -74.65% | -31.51% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | 766.00K | 632.00K | 768.98K | - | - | - | - |
| Cost of Revenue | - | - | 443.55K | - | - | - | - |
| Gross Profit | - | - | 325.44K | - | - | - | - |
| Operating Expenses | - | - | 20.92M | - | - | - | - |
| Operating Income | -17.79M | -18.47M | -20.60M | - | - | - | - |
| EBITDA | - | - | -21.40M | - | - | - | - |
| Interest Expense | - | - | 11.74K | - | - | - | - |
| Pretax Income | - | - | -21.79M | - | - | - | - |
| Tax Provision | - | - | 0 | - | - | - | - |
| Net Income | -16.35M | -18.71M | -21.86M | - | - | - | - |
| Diluted EPS | -0.91 | -0.98 | -1.07 | -0.61 | -0.58 | -0.62 | -0.28 |
| R&D Expense | 11.56M | 12.63M | 13.95M | 16.46M | 16.34M | 16.81M | 17.46M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 5.83M | 3.20M | 2.73M | - | - |
| Cost of Revenue | 3.93M | 2.90M | 1.86M | - | - |
| Gross Profit | 1.91M | 298.38K | 876.80K | - | - |
| Operating Expenses | 18.23M | 31.79M | 47.53M | - | - |
| Operating Income | -16.32M | -31.49M | -46.66M | - | - |
| EBITDA | -15.50M | -29.14M | -45.54M | - | - |
| Interest Expense | 1.03M | 648.71K | 67.09K | - | - |
| Pretax Income | -17.17M | -30.56M | -46.76M | - | - |
| Tax Provision | 0 | 0 | 0 | - | - |
| Net Income | -17.17M | -30.56M | -46.02M | - | - |
| Diluted EPS | - | -2.26 | -2.94 | -3.77 | -2.55 |
| R&D Expense | - | - | - | 51.45M | 69.12M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | 21.43M | 15.99M | 30.53M | 80.70M | 23.00M |
| Current Assets | 18.75M | 12.24M | 24.22M | - | - |
| Cash & Equivalents | 15.46M | 9.29M | 21.03M | - | - |
| Inventory | 549.82K | 355.62K | 442.35K | - | - |
| Receivables | 204.99K | 440.93K | 407.56K | - | - |
| Total Liabilities | 10.91M | 6.95M | 11.63M | 18.02M | 23.25M |
| Current Liabilities | 10.20M | 6.05M | 9.46M | 16.56M | 21.37M |
| Long Term Debt | - | - | 93.84K | - | - |
| Total Debt | 4.14M | 952.79K | 1.69M | - | - |
| Total Equity | 10.52M | 9.03M | 19.30M | 62.76M | -93.00K |
| Shares Outstanding | 35.94M | 35.94M | 35.94M | - | - |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -14.44M | -29.42M | -34.63M | -61.24M | -77.80M |
| Investing Cash Flow | -886.07K | -992.57K | -2.58M | -2.28M | -596.00K |
| Financing Cash Flow | 27.42M | 23.27M | 49.34M | 112.83M | 20.55M |
| Capital Expenditure | -582.24K | -1.67M | -2.39M | -2.27M | -1.95M |
| Free Cash Flow | -15.02M | -31.08M | -37.03M | -63.51M | -79.76M |
| Net Change in Cash | 12.09M | -7.14M | 12.13M | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | 32.7% | 9.3% | 32.1% | - | - |
| Operating Margin % | -279.9% | -983.8% | -1,706.0% | - | - |
| Net Margin % | -294.5% | -954.9% | -1,682.8% | - | - |
| ROE % | -163.1% | -338.3% | -238.4% | - | - |
| ROCE % | -145.2% | -316.8% | -221.4% | - | - |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | L1 Capital Pty Ltd | 7.99% | 7.79M | $52.73M |
| 2 | FMR, LLC | 7.05% | 6.87M | $46.50M |
| 3 | Blackrock Inc. | 5.92% | 5.77M | $39.07M |
| 4 | Sio Capital Management, LLC | 5.69% | 5.55M | $37.55M |
| 5 | Perceptive Advisors Llc | 3.51% | 3.43M | $23.19M |
| 6 | Nantahala Capital Management, LLC | 3.47% | 3.38M | $22.91M |
| 7 | Adar1 Capital Management, LLC | 3.23% | 3.15M | $21.29M |
| 8 | RA Capital Management, L.P. | 3.08% | 3.00M | $20.31M |
| 9 | BVF Inc. | 3.08% | 3.00M | $20.31M |
| 10 | Ensign Peak Advisors, Inc | 2.45% | 2.39M | $16.18M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AVR
Cantor Fitzgerald reiterates Anteris Technologies stock rating at Overweight - Investing.com
<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxObmdTQnU0d3FiWWxtUjJtcmFnYk9sQklXaWJ4WXozWUV2NEJfd3V2VDNHRElkRXBqWlJ6QllSQ0w3Nk54NXM3NmNwekJ4WElQcHhxZkItU3RUY05zVWd3TWNoYzR6bEx5dGhEd1A1MHlHMDdyNVhBc3ZXOWotamtUSDRyZ3c0NWt3WG9uZT…
Anteris Technologies Global (ASX:AVR) Stock Forecast & Analyst Predictions - Simply Wall Street
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxNNDcxYVpXTk1lZDlpdl9HNlRfVzdsaF9yaGFFSUJ1cXkxSTg2T3hTRXRnTWtZOWNpY1FISHhBRVNyOUdGbkFaaTNhZ29SMngwd2NGNmE4TTUxc093MEpPRk9USDd3Si12N0g5cTB2djBrSE5FaFc1ZGZTa1pPampPdG5kM3QtYXN1TnMyWk…
The Technical Signals Behind (AVR) That Institutions Follow - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxOOWJYUHFDbUpwdmVRcktUaTVrZVVrX21zQkVNNkxmSzRNYUx1VHF3RWd5OFlYczEtUE1LemdoR2hrOU1UNHJ2SkI4RU5kQ2NCRGdOY0M4bGFCTGJXb0RBaG5DeVJfWVE4V28wM2twNmhibS0tbDFxQVg5eUp6YXpwT1NNMzRUT2dnSGpuVn…
A 10% owner’s funds buy Anteris Technologies (AVR) shares on two October dates. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxQZ0tHekpuZU5vZFJmMHl6aE9KWmJzODgzWWpQckE0X2ZrTUswZUcyRXhWa3E4R0pNVTc2SUFUVno5SzJISEpmaDBQWXhYcUxKb1VDMER0VW1TOVdmb3lVOEhuZERxZnJjOVF2N2V3b0Z4bFdfTzNPRWdDcnNoR1lQZzIwTlZEeUdOVjFvUW…
Cantor Fitzgerald reiterates Anteris Technologies stock rating at Overweight By Investing.com - Investing.com Nigeria
<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxNTTc2S2NyekdUUHVFWkRCSFNfOVdVZ1hVc01NLWRiMElJTTVKZ2ZHZmloem9nQU53cHJ5Q0hhb1hhYUFQV093Rk9tNWhVa0VqNlV2NXc4SlROemNEVkdTMWZmeU9RS2wxUkFUdmo1WHllVzNwZXUxQTJhaldwM3ZrYV9xV29YLTFmakpQZ3…
Insider Stock Purchases: October 02, 2026 - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMihAFBVV95cUxOUUhBQ2ZlT0NOeGpuTjVnaHREVWVNNzhiWlQ2SUVZZnBZR1hUdERLM1JTVWFSVUtWODN2ME5Mdm1aeTBybllIOFl6SFAxeDZONDNkenZJYms1RGtlWFk1Tm4xeVJYRmJleXNnMXB3aWFIWmpndThWdkx4NkxFOFctVGc4RHY?oc=5" targ…
AVR — Frequently Asked Questions
What is the current share price of Anteris Technologies Global Corp. (AVR)?
As of 2026-10-23 16:27 PDT, Anteris Technologies Global Corp. (AVR) trades at $5.87 on NasdaqGM. Its 52-week range is $3.38 to $10.57.
What is the market capitalisation of AVR?
Anteris Technologies Global Corp. (AVR) has a market capitalisation of $571.40M on NasdaqGM.
What is the P/E ratio of AVR?
AVR trades at a trailing price-to-earnings (P/E) ratio of -3.01. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 2.62.
What is the return on equity (ROE) of AVR?
AVR has a return on equity (ROE) of -74.65%.
Is AVR a good stock to buy?
This page provides a data-driven analysis of Anteris Technologies Global Corp. (AVR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.